Report
Geir Hiller Holom
EUR 93.85 For Business Accounts Only

PhotoCure (Buy, TP: NOK84.00) - Set to meet 2024 targets

Q3 revenues were NOK120.2m (up 12% YOY) and EBITDA was NOK5m (Q3 2023 NOK3.3m). We still expect the company to meet its financial targets for 2024, and have largely maintained our 2024–2028e EPS. We have removed future potential Asieris milestone payments from our estimates, now viewing this as upside potential to our base case. Following a change of analyst, we have cut our target price to NOK84 (87), but reiterate our BUY as we continue to find the valuation attractive.
Underlying
PhotoCure ASA

Photocure is a Norwegian based specialty pharmaceutical company. Co. develops and commercializes solutions in several disease areas such as bladder cancer, colorectal cancer, HPV and precancerous lesions of the cervix, acne and other dermatologic conditions. Co. has one marketed product that Co. commercializes directly in the U.S. and the Nordic region is Hexvix®/Cysview®, for detection of bladder cancer.

Provider
DnB Markets
DnB Markets

DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.

 

Analysts
Geir Hiller Holom

Other Reports on these Companies
Other Reports from DnB Markets

ResearchPool Subscriptions

Get the most out of your insights

Get in touch